Announcements Trials
Browse Landscape

Status

No longer available 2Available 2Approved for marketing 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Neoplasms 14Carcinoma, Non-Small-Cell Lung 8Sarcoma 6Prostatic Neoplasms 6Pancreatic Neoplasms 6Neuroblastoma 6Multiple Myeloma 6Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Ovarian Neoplasms 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Hematologic Neoplasms 3Head and Neck Neoplasms 3Urinary Bladder Neoplasms 2Primary Myelofibrosis 2Pheochromocytoma 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neuroectodermal Tumors, Primitive 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2

Interventions

ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Available × Expanded_access × Cholangiocarcinoma × Clear all
NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06370013 2024-04-17

Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors

TransThera Sciences (Nanjing), Inc.

Available
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡